Live Breaking News & Updates on Antonio dassoro

Stay informed with the latest breaking news from Antonio dassoro on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Antonio dassoro and stay connected to the pulse of your community

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.

Mayo-clinic-in-rochester , Minnesota , United-states , American , Karthikv-giridhar , Tufiac-haddad , Antonio-dassoro , Houj-aurora , Digital-health , Mayo-clinic-comprehensive-cancer-center , Mayo-clinic-college-of-medicine , American-society-of-clinical-oncology-annual-meeting

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Minnesota , United-states , Tufiac-haddad , Antonio-dassoro , Practice-innovation , Mayo-clinic-comprehensive-cancer-center , Antoniod-assoro , Puma-biotechnology , Alisertib- , Aurka-pathway- , Endocrine-resistant-advanced-breast-cancer

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Philadelphia , Pennsylvania , United-states , American , Gina-cestari , Evan-dick , Laine-yonker , Joseph-rucker , Antonio-dassoro , Lauryn-werner , Exchange-commission , University-of-kansas

Context Therapeutics Inc poised to showcase its compounds at this year's American Association for Cancer Research (AACR) annual meeting

Context Therapeutics (NASDAQ:CNTX) Inc, the women's cancer-focused group, has said its compounds are set to be showcased at the upcoming American...

Louisiana , United-states , New-orleans , Philadelphia , Pennsylvania , American , Martin-lehr , Joseph-rucker , Antonio-dassoro , Lauryn-werner , American-association-for-cancer-research , Context-therapeutics

Context Therapeutics® Announces Acceptance of Five

Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET...

United-states , Philadelphia , Pennsylvania , American , Martin-lehr , Gina-cestari , Laine-yonker , Joseph-rucker , Antonio-dassoro , Lauryn-werner , Institut-curie , University-of-kansas

Minnesota Partnership awards 5 collaborative research grants for 2021

Minnesota Partnership for Biotechnology and Medical Genomics announced today their 2021 research awardees. This marks the partnership's 17th year of...

Minnesota , United-states , University-of-minnesota , Minnesotans , Michael-barry , David-masopust , Antonella-borgatti , Antonio-dassoro , Daniel-harki , Joseph-lillegard , Scott-kaufmann , Carol-lange

Minnesota Partnership awards five research grants

The grants total to $5 million for five Mayo-U of M teams to begin two-year projects.
Written By:
Post Bulletin staff reports |
3:53 pm, Jan. 21, 2021
×
The state-funded grants for these projects total nearly $5 million. Among the projects are a long-lasting COVID-19 vaccine, new treatments for breast and other cancers, and gene-editing techniques to prevent birth defects.
The five teams will initiate the two-year projects aimed at improving treatment of diseases that affect Minnesotans. Projects are selected based on the quality and rigor of the proposed research, importance of the medical need and potential of future commercialization.
Each team includes people from Mayo Clinic and the University of Minnesota. It’s required that the studies be collaborative and that the projects could not be pursued by either institution alone.

Minnesota , United-states , University-of-minnesota , Minnesotans , Michael-barry , David-masopust , Antonella-borgatti , Antonio-dassoro , Daniel-harki , Joseph-lillegard , Scott-kaufmann , Carol-lange